| Trial | Treatments | Patients | Method |
|---|
| OB 301 (mid-dose) | PHEN/TPM 7.5/46 mg (n=107) vs. placebo (n=109) 3 arms: PHEN/TPM 3.75/23 mg, PHEN/TPM
15/92 mg and placebo | | Parallel groups Sample size: 107/109 Primary endpoint: Weight loss at 28 weeks FU duration: 28 weeks |
| OB 302 (low-dose) | PHEN/TPM 3.75/23 mg (n=241) vs. placebo (n=514) | | Sample size: 241/514 Primary endpoint: Weight loss at 56 weeks FU duration: 56 weeks |
| CONQUER (mid-dose) (OB 303) | PHEN/TPM 7.5/46 mg (n=498) vs. placebo (n=994) | | Sample size: 498/994 Primary endpoint: Weight loss at 56 weeks FU duration: 56 weeks |
| CONQUER (high-dose) (OB 303) | PHEN/TPM 15/92 mg (n=995) vs. placebo (n=994)
|
| Sample size: 995/994 Primary endpoint: Weight loss at 56 weeks FU duration: 56 weeks
|
| OB 302 (high-dose) | PHEN/TPM 15/92 mg (n=512) vs. placebo (n=514)
|
| Sample size: 512/514 Primary endpoint: Weight loss at 56 weeks FU duration: 56 weeks
|
| OB 301 (high-dose) | PHEN/TPM 15/92 mg (n=108) vs. placebo (n=109) 3 arms: PHEN/TPM 3.75/23 mg, PHEN/TPM
15/92 mg and placebo
|
| Sample size: 108/109 Primary endpoint: Weight loss at 28 weeks FU duration: 28 weeks
|
